Stockreport

MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten

MYOKARDIA  (MYOK) 
Last myokardia earnings: 2/27 04:05 pm Check Earnings Report
PDF Mavacamten’s Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM [Read more]